The expanding phenotype of POMT1 mutations: from Walker-Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation
- PMID: 16575835
- DOI: 10.1002/humu.20313
The expanding phenotype of POMT1 mutations: from Walker-Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation
Abstract
The importance of O-glycosylation of alpha-dystroglycan (alpha-DG) is evident from the identification of POMT1 mutations in Walker-Warburg syndrome (WWS). Approximately one-fifth of the WWS patients show mutations in POMT1, which result in complete loss of protein mannosyltransferase activity. WWS patients are characterized by congenital muscular dystrophy (CMD) with severe brain and eye abnormalities. This suggests a crucial role for alpha-DG during development of these organs and tissues. Here we report new POMT1 mutations and polymorphisms in WWS patients. In addition, we report different compound heterozygous POMT1 mutations in four unrelated families that result in a less severe phenotype than WWS, characterized by CMD with calf hypertrophy, microcephaly, and mental retardation. Compared to WWS patients, these patients have milder structural brain abnormalities, and eye abnormalities were absent, except for myopia in some cases. In these patients we postulate that one or both transcripts for POMT1 confer residual protein O-mannosyltransferase activity. Our data suggest the existence of a disease spectrum of CMD including brain and eye abnormalities resulting from POMT1 mutations.
(c) 2006 Wiley-Liss, Inc.
Similar articles
-
Mutations of the POMT1 gene found in patients with Walker-Warburg syndrome lead to a defect of protein O-mannosylation.Biochem Biophys Res Commun. 2004 Dec 3;325(1):75-9. doi: 10.1016/j.bbrc.2004.10.001. Biochem Biophys Res Commun. 2004. PMID: 15522202
-
New POMT2 mutations causing congenital muscular dystrophy: identification of a founder mutation.Neurology. 2007 Sep 18;69(12):1254-60. doi: 10.1212/01.wnl.0000268489.60809.c4. Epub 2007 Jul 18. Neurology. 2007. PMID: 17634419
-
POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome.J Med Genet. 2005 Dec;42(12):907-12. doi: 10.1136/jmg.2005.031963. Epub 2005 May 13. J Med Genet. 2005. PMID: 15894594 Free PMC article.
-
Walker-Warburg syndrome.Orphanet J Rare Dis. 2006 Aug 3;1:29. doi: 10.1186/1750-1172-1-29. Orphanet J Rare Dis. 2006. PMID: 16887026 Free PMC article. Review.
-
Glyc-O-genetics of Walker-Warburg syndrome.Clin Genet. 2005 Apr;67(4):281-9. doi: 10.1111/j.1399-0004.2004.00368.x. Clin Genet. 2005. PMID: 15733261 Review.
Cited by
-
Dystroglycan glycosylation and muscular dystrophy.Glycoconj J. 2009 Apr;26(3):349-57. doi: 10.1007/s10719-008-9182-0. Epub 2008 Sep 5. Glycoconj J. 2009. PMID: 18773291 Review.
-
Structure of the eukaryotic protein O-mannosyltransferase Pmt1-Pmt2 complex.Nat Struct Mol Biol. 2019 Aug;26(8):704-711. doi: 10.1038/s41594-019-0262-6. Epub 2019 Jul 8. Nat Struct Mol Biol. 2019. PMID: 31285605 Free PMC article.
-
Mammalian O-mannosylation pathway: glycan structures, enzymes, and protein substrates.Biochemistry. 2014 May 20;53(19):3066-78. doi: 10.1021/bi500153y. Epub 2014 May 7. Biochemistry. 2014. PMID: 24786756 Free PMC article. Review.
-
Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease.Neurogenetics. 2007 Nov;8(4):279-88. doi: 10.1007/s10048-007-0096-y. Epub 2007 Sep 29. Neurogenetics. 2007. PMID: 17906881
-
Midbrain-hindbrain involvement in lissencephalies.Neurology. 2009 Feb 3;72(5):410-8. doi: 10.1212/01.wnl.0000333256.74903.94. Epub 2008 Nov 19. Neurology. 2009. PMID: 19020296 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous